Paperpal Prime Logo

IN SILICO PHARMACOLOGY : Impact Factor & More

eISSN: 2193-9616pISSN: 2193-9616
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on IN SILICO PHARMACOLOGY

IN SILICO PHARMACOLOGY Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
Overview
Publisher SPRINGER HEIDELBERG
Frequency Continuous publication
General Details
FrequencyContinuous publication
Publisher URLVisit website
Website URLVisit website
View less

Planning to publish in IN SILICO PHARMACOLOGY ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in IN SILICO PHARMACOLOGY

In silico identification of\u2002novel PTP1B inhibitors by the investigation of molecular mechanism, QSAR, and DFT studies
  • 22 Jul 2026
  • In Silico Pharmacology
Insilico study to unveil the characteristics of pseudoRab GTPases in pathogenic protozoan parasites: Entamoeba histolytica.
  • 11 Jul 2026
  • In silico pharmacology
Targeting A549 cells: the synthesis and multi-omic characterization of a high-affinity hydrazone derivative.
  • 20 Jun 2026
  • In silico pharmacology
Antibacterial flavonoid derivatives: in silico ADMET, DFT, Molecular Docking, MD Simulation and in vitro verification.
  • 4 Jun 2026
  • In silico pharmacology
Multistep molecular assessment of pediocin-like bacteriocins as antifungal agents targeting secreted aspartic protease 2 (SAP2) of Candida albicans through computational modeling and molecular dynamics
  • 26 May 2026
  • In Silico Pharmacology
Molecular docking and dynamics simulations of aptamers for sandwich-type detection of Trichomonas vaginalis
  • 28 Apr 2026
  • In Silico Pharmacology
In silico identification of\u2002novel PTP1B inhibitors by the investigation of molecular mechanism, QSAR, and DFT studies
  • 22 Jul 2026
  • In Silico Pharmacology
Insilico study to unveil the characteristics of pseudoRab GTPases in pathogenic protozoan parasites: Entamoeba histolytica.
  • 11 Jul 2026
  • In silico pharmacology
Targeting A549 cells: the synthesis and multi-omic characterization of a high-affinity hydrazone derivative.
  • 20 Jun 2026
  • In silico pharmacology
Antibacterial flavonoid derivatives: in silico ADMET, DFT, Molecular Docking, MD Simulation and in vitro verification.
  • 4 Jun 2026
  • In silico pharmacology
Multistep molecular assessment of pediocin-like bacteriocins as antifungal agents targeting secreted aspartic protease 2 (SAP2) of Candida albicans through computational modeling and molecular dynamics
  • 26 May 2026
  • In Silico Pharmacology
Molecular docking and dynamics simulations of aptamers for sandwich-type detection of Trichomonas vaginalis
  • 28 Apr 2026
  • In Silico Pharmacology

FAQs on IN SILICO PHARMACOLOGY